Helicobacter-pylori: New developments and treatments

CMAJ. Canadian Medical Association Journal

Volumn 156, Issue 11, 1997, Pages 1565-1574

  Veldhuyzen Van Zanten, Sander J O ^a,d   Sherman, Philip M ^b   Hunt, Richard H ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; TETRACYCLINE;

DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; REVIEW; STOMACH ULCER;

EID: 0030973319     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Veldhuyzen van Zanten SJO, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 1994;150:177-85.
2. International Agency for Research in Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-240.
3. NIH Consensus Conference Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
4. Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen XJ, Marshall BJ, et al. Duodenal ulcer treatment with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994;343:258-260.
5. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyeri W, Bolton GH, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9:41-6.
6. Veldhuyzen van Zanten SJO, Pollak PT, Best LM, Bezanson GS, Marrie TJ. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994;169:434-7.
7. Sung JJY, Chung SCS, Ling TKW, Yung MY, Leung VKS, Ng EKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-42.
8. Kuipers EJ. Helicobacter pylori and peptic ulcer disease. Aliment Pharmacol Ther 1995;9(suppl 2):59-69.
9. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister A. Lack of discriminant value of dyspepsia subgroups in patients referred for upper cndoscopy. Gastroenterology 1993;105:1378-86.
10. Wyatt JI, Gray SF. Dectection of Campylobacter pylori by histology. In: Rathbone BJ, Heatley RV, editors. Campylobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific Publications, 1989:63-8.
11. Goodwin CS. Campylobacter pylori detection and cultures. In: Rathbone BJ, Heatley RV, editors. Campylobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific Publications, 1989:60-2.
12. Marshall BJ, Warren J, Francis GJ, Langton SR, Goodwin CS, Blincow ED. Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol 1987;82:200-10.
13. 13C-urea breath test. In: Rathbone BJ, Heatley RV, editors. Campylobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific Publications, 1989:94-105.
14. 14C-Urea breath test for the detection of Helicobacter pylori. Am J Gastroenterol 1990;85:399-403.
15. Stacey AR, Newell DG. The serology of Campylobacter pylori infections. In: Rathbone BJ, Heatley RV, editors. Campylobacter pylori and gastroduodenal disease. Oxford: Blackwell Scientific Publications, 1989:74-82.
16. Best LM, Veldhuyzen van Zanten SJO, Bezanson GS, Haldane DJM, Malatjalian DM. Serological detection of Helicobacter pylori by a flow microsphere immunofluorescence assay. J Clin Microbiol 1992;30:2311-7.
17. Wilcox MH, Dent THS, Hunter JO, Grray JJ, Brown DFJ, Wight DGD, et al. Accuracy of serology for the diagnosis of Helicobacter pylori infection: a comparison of eight kits. J Clin Pathol 1996;49:373-6.
18. Loy CT, Irwig LM, Katelaris PH, Talle NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-44.
19. Fallone CA, Wild GE, Goresky CA, Barkun AN. Evaluation of IgA and IgG serology for the detection of Helicobacter pylori infection. Can J Gastroenterol 1995;9:105-11.
20. O'Brien B, Goeree R, Mohamed H, Hunt RH. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcers in Canada. Arch Intern Med 1995;155:1958-64.
21. Fennerty MB. "Cure" of Helicobacter pylori. Clinically indicated and economically wise. Arch Intern Med 1995;155:1929-31.
22. Labenz J, Tillenburg B, Peitz U, Sollbohmer M, Stolte M, Borsch G. Long-term clinical course of ulcer disease and incidence of reflux esopahgitis in a large cohort of duodenal ulcer patients followed after eradication of Helicobacter pylori [abstract]. Gut 1995;37(suppl 1):A6.
23. Schutze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995; 36:831-3.
24. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994;55:19-23.
25. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of H. pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993;28:939-42.
26. Rokkas TH, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995;41:1-4.
27. Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar C-H. Helicobacter pylori eradication reduces the risk of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995;41:5-7.
28. Jensen DM, Cheng S, Kovacs TOG, Randall G, Jensen ME, Reedy T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994;330:382-6.
29. Borody TJ, George LL, Brandl S, Andrews P, Ostapowicz N, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991;86:1154-7.
30. Laine L, Martin-Sorensen M, Weinstein W. NSAID-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992;87:1398-402.
31. Veldhuyzen van Zanten SJO. H pylori and NSAIDS: a meta-analysis on interactions of acute gastroduodenal injury, gastric and duodenal ulcers and upper gastrointestinal symptoms. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic research to clinical cure. London: Kluwer Academic Publishers; 1994.
32. Parsonnet J, Friedman G, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N et al. Helicobacter pylori and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
33. Nomura A, Stemmerman GN, Chyou PH, Kato J, Perez Perez GI, Blaser MJ. Helicobacter pylori and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
34. Forman D, Sitas F, Newell DG, Stacey AR, Boreham J, Peto R, et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990;46:608-11.
35. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1194;330: 1267-71.
36. Wotherspoon AC, Ortz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338:1175-6.
37. Wotherspoon AC, Doglioni C, Diss TC, Pan LX, Moschini A, Deboni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575-7.
38. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;345:1591-4.
39. Munoz N, Pisani P. Helicobacter pylori and gastric cancer. Eur J Gastroenterol Hepatol 1994;6:1097-103.
40. Beaslely RP, Hwang L-Y, Lin C-C, Chien C-S. Hepatocellular carcinoma and hepatitis B virus. Lancet 1981;2:1129-33.
41. Sakuma K, Takahara T, Okuda K, Tsuda F, Mayumi M. Prognosis of hepatitis B virus surface antigen carriers in relation to routine liver function tests: a prospective study. Gastroenterology 1982;83:114-7.
42. Forman D, Webb PM. Helicobacter pylori and gastric cancer: the significance of the problem. Chapter 43. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic research to clinical cure. London: Kluwer Academic Publishers; 1994:461-8.
43. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GNJ, et al. Intestinal metaplasia and Helicobacter pylori. An endoscopic bioptic study of the gastric antrum. Gut 1992;33:16-20.
44. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
45. National Cancer Institute of Canada. Canadian Cancer Statistics, 1993. Toronto: The Institute; 1993:48-53.
46. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9(suppl 2):45-51.
47. Lambert JR. The role of Helicobacter pylori in non-ulcer dyspepsia. A debate - For. Gastroenterol Clin North Am 1993;22:141-51.
48. Talley NJ. The role of Helicobacter pylori in non-ulcer dyspepsia. A debate - Against. Gastroenterol Clin North Am 1993;22:153-67.
49. Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gaatroenterol 1996;91:660-73.
50. Talley NJ. A critique of therapeutic trials in Helicobacter pylori positive functional dyspepsia. Gastroenterology 1994;106:1174-83.
51. Veldhuyzen van Zanten SJO. A systematic overview (meta-analysis) of outcome measures in patients with Helicobacter pylori gastritis trials and functional dyspepsia. J Clin Epidemiol 1993;46:273-9.
52. Patchett S, Beattie S, Leen E, Keane C, O'Morain C. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ 1991;303:1238-40.
53. McCarthy C, Patchett S, Collins RM, Beattie S, Keane C, O'Morain C, et al. Long-term prospective study of Helicobacter pylori in non-ulcer dyspepsia. Dig Dis Sci 1995;40:114-9.
54. Trespi E, Broglia F, Villani L, Luinetti O, Fiocca R, Solcia E. Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication. Scand J Gastroenterol 1994; 29:884-8.
55. Sheu B-S, Lin C-Y, Lin X-Z, Shiesh S-C, Yang H-B, Chen C-Y, et al. Long-term outcome of triple therapy in Helicobacter pylori-related non-ulcer dyspepsia: a prospective controlled assessment. Am J Gastroenterol 1996;91:441-7.
56. Veldhuyzen van Zanten SJO. Is the decreasing resistance to treat Helicobacter pylori the result of improved efficacy? Can J Gastroenterol 1994;8:233-4.
57. Chiba N, Rao BV, Rademaker JW, Hunt RH, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.
58. Borody TJ, Brandl S, Andrews P, Ferih N, Jankiewicz E, Hyland L. Use of high efficacy, lower dose triple therapy to reduce side-effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:33-8.
59. Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, et al. Helicobacter pylori eradication: efficacy and side-effect profile of a combination of omeprazole, amoxicillin and metronidazole compared with four alternative regimens. Q J Med 1993;86:743-60.
60. Penston JG. Helicobacter pylori eradication: understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-89.
61. Graham DY, Lew GM, Malaty HM, Evans PG, Evans DJ, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
62. Logan RPH, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH. One week eradication regimen for Helicobacter pylori. Lancet 1991;338: 1249-52.
63. Veldhuyzen van Zanten SJO, Hunt RH, Cockeram A, Schep G, Malatjalian D, Matisko A, et al. Adding omeprazole 20 mg once a day to metronidazole/amoxicillin treatment of Hp-gastritis: a randomized double blind trial. The importance of metronidazole resistance [abstract A417]. Am J Gastroenterol 1994;89:1389.
64. Becx MCMJ, Jansen AJHM, Clasener HAL, de Koning RW, et al. Metronidazole-resistant Helicobacter pylori. Lancet 1990;1:539-40.
65. Glupczynski Y, Burette A, De Koster A, Nyst JF, Deltenre M, Cadranel S, et al. Epidemiological factors associated with metronidazole resistance in Helicobacter pylori. Lancet 1990;1:976-7.
66. Weil J, Bell GD, Powell K, Jobson R, Trowell JE, Gant P, et al. Helicobacter pylori and metronidazole resistance. Lancet 1990;2:270.
67. Fallone CA, Loo VG, Barkun AN, De Souza B, Lavalles J, Wickham C. Rate of Helicobacter pylori resistance to metronidazole, clarithromycin and six other agents [abstract S33]. Can J Gastroenterol 1996;10(suppl A):30A.
68. Best LM, Haldane DJM, Veldhuyzen van Zanten SJO. Susceptibility of H. pylori in Canada to clarithromycin and metronidazole [abstract 1A:39]. Gut 1996;39(suppl 2):A13.
69. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJO. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori. Repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J Bacteriol 1996;178:4822-9.
70. Kaihovaara P, Hook-Nikane J, Salmela KS, Roine RP, Kosunen TU. Flavodoxin dependent metronidazole reduction and acetate production by Helicobacter pylori [abstract]. Gastroenterology 1994;106:A707.
71. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988;41:207-10.
72. Glupczynski Y. In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of Helicobacter pylori infection. In: Malfertheiner P, Ditschuneit H, editors. Helicobacter pylori, gastritis and peptic ulcer. Berlin: Springer Verlag; 1990:49-58.
73. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990;85:1545-51.
74. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole: a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. J Antimicrob Chemother 1991;35:490-6.
75. Loo VG, Sherman P, Matlow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. J Antimicrob Chemother 1992;36:1133-5.
76. Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, et al. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991;5:309-13.
77. Hui WM, Lam SK, Ho J, Lai CL, Lok AS, Ny MM, et al. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci 1991;36(5):577-82.
78. Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Lamers CBHW, Jansen JBMJ, Snel P, et al. Long-term omeprazole therapy does not affect the Helicobacter pylori status in most patients. Scand J Gastroenterol 1993;28:978-80.
79. Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, et al. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991:5:309-13.
80. Bayerdorffer, E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108:1412-7.
81. Collins R, Beattie S, Xia HX, O'Morain C. High-dose omeprazole and amoxicillin in the treatment of Helicobacter pylori-associated duodenal ulcer. Aliment Pharmacol Ther 1993;7:313-5.
82. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994;29:16-23.
83. Chiba N, Wilkinson JM, Hunt RH. Clarithromycin or amoxicillin dual and triple therapies in Helicobacter pylori eradication: a meta-analysis [abstract T124]. Gut 1995;37:A31.
84. Laine L, Stein C, Neil G. Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized study employing optimal dosing. Am J Gastroenterol 1995;90:1407-10.
85. Al-Assi MT, Cole RA, Karttunen TJ, Elzimaity H, Genta RM, Graham DY. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol 1995;90:1411-4.
86. Chiba N, Wilkinson JM, Hunt RH. Clarithromycin or amoxicillin dual and triple therapies in Helicobacter pylori eradication: a meta-analysis [abstract]. Gut 1995;37(suppl 2):A31.
87. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med 1996; 100(suppl 5A):425-505.
88. Bazzoli F, Zagari RM, Fossi P, Pozzato P, Alampi G, Simoni P, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7.
89. Maoyyedi P, Axon ATR. Efficacy of a new one week therapy regime in eradicating Helicobacter pylori. Gut 1994;35(suppl 2):S62.
90. Lind T, Veldhuyzen van Zanten SJO, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week therapies combining omeprazole with two antimicrobials - the MACH 1 Study. Helicobacter 1996;1:138-44.
91. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized double blind trial. Am J Gastroenterol 1993;88:1860-4.
92. Chiba N. Lansoprazole or pantoprazole triple therapies in Helicobacter pylori eradication: a meta-analysis [abstract S24]. Can J Gastroenterol 1997;11(suppl A):27A.
93. Schutze K, Hentschel E. Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Zeitschrift Gastroenterologie 1995;33:651-3.
94. Schwarz HS, Krause R, Siepman N, Haber M, Weissfeld A, Kidd S, et al. Seven-day triple therapy with lansoprazole, clarithromycin and metronidazole for the cure of Helicobacter pylori infection. A short report. Helicobacter 1996;1: 251-5.
95. Jaup BK. Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Helicobacter 1996; 1:260-1.
96. Schwarz H, Krause R, Sahbs B. Triple versus dual therapy with lansoprazole, clarithromycin and/or amoxicillin in the eradication of Helicobacter pylori [abstract 641]. Am J Gastroenterol 1996;91:2047.
97. De Boer W, Driessen W, Jansz A, Tytgat GNJ. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995;335:817-20.
98. Hosking SW, Ling TK, Yung MY, Cheng A, Chung SC, Leung JW, et al. Randomised controlled trial of short-term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 1992;305:502-4.
99. Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995;37:477-81.
100. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, Adams L, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating Helicobacter pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
101. Megraud F, Brassens-Rebbe MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-3.
102. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991;13:42-59.
103. Doidge C, Gust I, Lee A, Buck F, Hazell S, Manne U. Therapeutic immunisation against Helicobacter pylori infection. Lancet 1994;343:914-5.
104. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney AC, Haas R, et al. Oral immunization with Helicobacter pylori urease B subunit as treatment against Helicobacter pylori infection in mice. Gastroenterology 1995;109:115-21.
105. Cuenca R, Blanchard Tg, Czinn SJ, Nedrud JG, Monath TP, Lee CK, et al. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 1996;110:1770-5.
106. Lee A. Therapeutic immunization against Helicobacter pylori infection. Gastroenterology 1996;110:2003-6.
107. Chiba N. Treatment regimens for Helicobacter pylori: the pros and cons. Can J Diagn 1995;(suppl Nov):7-10.
108. Graham DY, de Boer WA, Tytgat GN. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
109. Best L, Veldhuyzen van Zanten SJO. Clarithromycin susceptability of Helicobacter pylori [abstract]. Can J Gastroenterol 1996;10(suppl A):24A.
110. Cayla R, Zerbib F, Talbi P, Megraud F, Lamouliatte H. Pre- and post-treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure [abstract 217]. Gut 1995;37(suppl 1):A55.
111. Glupczynski Y, Goutier S, Van den Boore C, Butzler JP, Burete A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994 [abstract 223]. Gut 1995;37(suppl 1):A56.
112. Chiba N, Hunt RH. Bismuth, metronidazole and tetracycline (BMT) + acid suppression in H. pylori eradication: a meta-analysis [abstract 4A:27]. Gut 1996;39(suppl 2):A36.